Search Within

Department of Medicine

Formats
  1. Journal Article (19618)
  2. Meeting Abstract (16046)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22348)
  2. Hematologic Malignancies, Division of (13287)
  3. Center for Hematologic Malignancies (11069)
  4. GSK Faculty (10653)
  5. Survivorship Research (9346)
  6. Division of Subspecialty Medicine (7554)

More Groups

People
  1. Robert Motzer (1249)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1118)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2291)
  6. Nature Publishing Group (2121)

More Publishers

Results (39669)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: Results of a multicenter phase II experience
    Meeting Abstract

    O'connor, O.; Wright, J.; Moskowitz, C.; Straus, D.; Portlock, C.; Hamlin, P.; Neylon, E.; Evans, A.; Winter, J.; Gordon, L.; more...
    Annals of Oncology (2005)

    Fulltext@MSK | Save
  • Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone anlog BMS 247550 induces major and durable remissions in very drug resistant disease
    Meeting Abstract

    O'connor, O.; Straus, D.; Moskowitz, C.; Hamlin, P.; Portlock, C.; Gerecitano, J.; Neylon, E.; Colevas, D.; Zelenetz, A.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Pralatrexate (10-propargyl-10-deazaaminopterin (PRX)), a novel antifolate, effects durable complete remissions (CR) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity
    Meeting Abstract

    O'connor, O.; Hamlin, P. A.; Neylon, E.; Moskowitz, C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Cortelli, B.; Zelenetz, A. D.; Fleisher, M.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent R00281501 by dynamic contrast enhanced MRI at 1.5T
    Meeting Abstract

    Muruganandham, M.; Lupu, M.; Dyke, J. P.; Matei, C.; Kolinsky, K.; Higgins, B.; Koutcher, J. A.
    Clinical Cancer Research (2005)

    Fulltext@MSK | Save
  • Phase 2 trials of SU1 1248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC)
    Meeting Abstract

    Motzer, R. J.; Rini, B. I.; Michaelson, M. D.; Redman, B. G.; Hudes, G. R.; Wilding, G.; Bukowski, R. M.; George, D. J.; Kim, S. T.; Baum, C. M.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Sunitinib malate (SU11248) shows antitumour activity in patients with metastatic renal cell carcinoma: Updated results from phase II trials
    Meeting Abstract

    Motzer, R.; Rini, B.; Michaelson, M.; Redman, B.; Hudes, G.; Wilding, I.; Bukowski, R.; George, D.; Kim, S.; Baum, C.
    EJC Supplements (2005)

    Fulltext@MSK | Save
  • Phase II study of boriezomib for castrate metastatic prostate cancer (PC)
    Meeting Abstract

    Morris, M. J.; Beekman, K. W.; Kelly, W. K.; Slovin, S. F.; Shaffer, D.; Eicher, C.; Chu, E.; Curley, T.; Delacruz, A.; Scher, H. I.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors
    Meeting Abstract

    Monk, J. P.; Calero-Villalona, M.; Dupont, J.; Larkin, J.; Otterson, G.; Spriggs, D.; Hannah, A. L.; Cropp, G. F.; Johnson, R. G.; Hensley, M. L.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma
    Meeting Abstract

    Molina, A. M.; Advani, R.; Reddy, S.; Hoppe, R.; Friedberg, J. W.; Sadan, S.; Myskowski, P.; Kim, Y. H.; Horwitz, S. M.
    Blood (2005)

    Fulltext@MSK | Save
  • Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Misbah, S. A.; Shaheen, P. E.; Elson, P. J.; Negrier, S.; Motzer, R. J.; Andresen, S. W.; Bukowski, R. M.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save